The spectrum of medical therapies to treat COVID-19 is rapidly evolving. Currently, Sotrovima and Bebtelovimab are therapeutic products available for Iowans that have received Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA). These therapeutics are for the treatment of mild to moderate COVID-19 in nonhospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization. These medications are used at different times, including for the prevention and treatment of illness due to COVID-19.
Oral Antivirals
Oral antiviral drugs are prescription medicines that fight against the COVID-19 virus in the body. Antiviral drugs are not sold over the counter, and can only be received from a licensed healthcare provider. Antiviral drugs are different from antibiotics, which fight against bacterial infections. Two products have been granted EUAs by the FDA.
-
Molnupiravir (Merck) - these are activated through metabolization in the body and disrupts the virus's reproduction. This is administered orally via a pill.
-
Paxlovid (Pfizer) - these work inside the cell inhibiting an enzyme that the virus makes to replicate itself. This is administered orally as a pill.
Pre-exposure Prophylaxis (PrEP) and Monoclonal Antibodies (mAbs)
There are no currently authorized mAbs and PrEP products at this time.
Click the Chart below to access links to the EUAs and Fact Sheets
Questions
Contact the Combat COVID Monoclonal Antibodies Call Center at 877-332-6585